



Virtual Connected Education

SAVE THE DATE!

Wednesday 16 October 2019 • 18:00 - 20:00 GMT • 19:00 - 21:00 CET

Meeting: Metastatic Breast Cancer



Eli Lilly & Company invites you to an interactive, virtual meeting on the topic

From the Congress to the Clinic: How Scientific Data Disclosures on CDK4/6 Inhibitors are Impacting Clinical Decisions in Patients with HR+/HER2- mBC

to discuss the clinical implications for these patients of the latest research. Connecting sites across Europe, this meeting will provide the opportunity to follow lectures presented by an expert faculty, as well as to participate in the discussion between sites, ask the speakers questions, and share your opinions on various clinical cases.

Locations



London, UK • Manchester, UK •
Connecting sites in Europe



Virtual Connected Education

SAVE THE DATE!

Wednesday 16 October 2019 • 18:00 - 20:00 GMT • 19:00 - 21:00 CET

Meeting: Metastatic Breast Cancer



AGENDA

From the Congress to the Clinic: How Scientific Data Disclosures on CDK4/6 Inhibitors are Impacting Clinical Decisions in Patients with HR+/HER2- mBC

Introduction and welcome	Alistair Ring, UK
Key highlights from 2019 in HR+/HER2- mBC	Andrew Wardley, UK
Clinical case discussions – managing patients with HR+/HER2- mBC	
Clinical case 1	Connecting site
Clinical case 2	Connecting site
Clinical case 3	Connecting site
Summary and close	Alistair Ring, UK